More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.46B
EPS
0.22
P/E ratio
120.8
Price to sales
7.2
Dividend yield
--
Beta
1.667996
Previous close
$27.15
Today's open
$27.13
Day's range
$26.84 - $27.59
52 week range
$19.30 - $34.80
show more
CEO
Todd Franklin Watanabe
Employees
354
Headquarters
Westlake Village, CA
Exchange
Nasdaq Global Select
Shares outstanding
126455033
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
New INTEGUMENT-INFANT trial results demonstrate improvements in itch, reductions in symptoms, and improvements in quality of life for infants with atopic dermatitis and their families Findings further support investigational ZORYVE cream 0.05% to help address unmet needs in infants aged 3 to
GlobeNewsWire • Nov 13, 2026

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 58,500 restricted stock units (RSUs) of Arcutis common stock as well as options to purchase an aggregate of 17,000 shares of Arcutis' common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of November 2, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewsWire • Nov 6, 2026

Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily ZORYVE cream treatment to individuals with moderate to severe atopic dermatitis Builds on existing evidence of ZORYVE cream 0.15% for individuals ages 6 and older and ZORYVE cream 0.05% for children ages 2 to 5 with mild to moderate atopic dermatitis WESTLAKE VILLAGE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first participant has been enrolled in a Phase 3, double-blind, randomized, vehicle-controlled study, INTEGUMENT-3.
GlobeNewsWire • Nov 5, 2026

Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
Biotech stocks offered a mixed third-quarter bag on Thursday, with Arcutis reversing and BeOne Medicines surging deeper into its buy zone.
Investors Business Daily • Nov 5, 2026

Arcutis Biotherapeutics Q3 Earnings Call Highlights
Arcutis Biotherapeutics NASDAQ: ARQT raised its full-year 2026 net revenue guidance after third-quarter sales of its ZORYVE skin treatments rose 45% from a year earlier, driven primarily by increased patient demand.
MarketBeat • Nov 5, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. ( ARQT ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Brian Schoelkopf - Head of Investor Relations Todd Watanabe - President, CEO & Director Robert Lisicki - Interim Executive VP & Chief Commercial Officer Patrick Burnett - Executive VP & Chief Medical Officer Latha Vairavan - Senior VP & Chief Financial Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities, LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Lin Tsai - Jefferies LLC, Research Division Ikenna Okafor - TD Cowen, Research Division Parth Patel - Morgan Stanley, Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division John Gionco - Needham & Company, LLC, Research Division Jin Law - Goldman Sachs Group, Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by.
Seeking Alpha • Nov 5, 2026

Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growth Raised 2026 full-year net product sales guidance to $535 million–$545 million Partnered with World Champion gymnast Simone Biles to launch the Skin to Believe In awareness campaign for individuals living with inflammatory skin conditions Remains on track to disclose topline results from Phase 2 trial of ZORYVE foam 0.3% in individuals with vitiligo and decision on program advancement in Q4 of 2026 Maintained positive operating cash flow for the quarter with $18.9 million of net cash provided by operating activities WESTLAKE VILLAGE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended September 30, 2026, and provided a business update.
GlobeNewsWire • Nov 4, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates
Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.06 per share a year ago.
Zacks Investment Research • Nov 4, 2026

Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 28, 2026

Arcutis Appoints Rob Scott, MD to Board of Directors
Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and pioneer.
GlobeNewsWire • Oct 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Arcutis Biotherapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.